Search - tctmd.com

Displaying 1 - 20 of 28

Sort: Relevancy | Date

Presentation ACC 2025

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Presenter: Isabelle Mahé

March 29, 2025

Presentation ESC 2024

OCEANIC-AF: Asundexian vs. Apixaban in Patients with Atrial Fibrillation

Presenter: Manesh R. Patel

September 01, 2024

Presentation THT 2024

Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices (DOAC LVAD) Study

Presenter: Palak Shah

March 05, 2024

Presentation AHA 2023

The Artesia trial: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Presenter: Jeff Healey

November 16, 2023

Presentation TCT 2019

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Presenter: Amit Vora

September 28, 2019

Presentation TCT 2019

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Presenter: Stephan Windecker

September 26, 2019

Presentation ACC 2019

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial

Presenter: Renato Lopes

March 18, 2019

Presentation TCT 2017

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

Presenter: Deepak L. Bhatt, C. Michael Gibson, Renato D. Lopes

November 01, 2017

Presentation

Apixaban in Patients With Atrial Fibrillation After TAVR

Presenter: J. Seeger

January 03, 2017

Presentation TCT 2016

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Roxana Mehran

November 01, 2016

Presentation TCT 2015

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Pascal Vranckx, Renato D. Lopes

October 14, 2015

Presentation TCT 2015

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

Presenter: Lisa K. Jennings, Matthew T. Roe

October 14, 2015

Presentation TCT 2014

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Presenter: E. Magnus Ohman, Freek W.A. Verheugt, C. Michael Gibson, Christopher B. Granger

September 15, 2014

Presentation

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Presenter: Paul Dorian

February 20, 2014

Presentation

Efficacy and Safety of Apixaban Following Cardioversion for A-fib: ARISTOTLE Insights

Presenter: Greg Flaker

November 14, 2013

Presentation

High Sensitivity Troponin T and Risk Stratification in Patients with A-fib on Apixaban or Warfarin

Presenter: Ziad Hijazi

October 02, 2013

Presentation ESC 2013

Apixaban versus Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Findings from the ARISTOTLE Trial

Presenter: Alvaro Avezum

September 03, 2013

Presentation

Apixaban Vs. Warfarin in Patients with Atrial Fibrillation According to Prior Warfarin Use

Presenter: David Garcia

August 05, 2013

Presentation

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Presenter: Stefan H. Hohnloser

August 01, 2013

Presentation

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

Presenter: Giancarlo Agnelli

July 02, 2013

Advertisement

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

OCEANIC-AF: Asundexian vs. Apixaban in Patients with Atrial Fibrillation

Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices (DOAC LVAD) Study

The Artesia trial: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI - Design, Rationale, and Status

Apixaban in Patients With Atrial Fibrillation After TAVR

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Apixaban: Analysis of Efficacy, Safety, and Special Considerations

Apixaban in ACS and Atrial Fibrillation: Comparison to Warfarin and Aspirin

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Efficacy and Safety of Apixaban Following Cardioversion for A-fib: ARISTOTLE Insights

High Sensitivity Troponin T and Risk Stratification in Patients with A-fib on Apixaban or Warfarin

Apixaban versus Warfarin in Patients with Atrial Fibrillation and Valvular Heart Disease: Findings from the ARISTOTLE Trial

Apixaban Vs. Warfarin in Patients with Atrial Fibrillation According to Prior Warfarin Use

The Effects of Apixaban on Hospitalizations in Patients With Different Types of Atrial Fibrillation

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content